SB 623

Drug Profile

SB 623

Alternative Names: Modified bone marrow derived mesenchymal stem cells - SanBio; SB623

Latest Information Update: 02 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SanBio
  • Developer SanBio; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
  • Class Antidementias; Antiparkinsonians; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Nerve growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain injuries; Stroke
  • Preclinical Dry age-related macular degeneration; Parkinson's disease; Retinitis pigmentosa; Spinal cord injuries
  • Research Alzheimer's disease

Most Recent Events

  • 02 Jul 2018 SB 623 is still in preclinical development for Dry age-related macular degeneration in USA (SanBio pipeline, July 2018)
  • 02 Jul 2018 Preclinical trials in Retinitis pigmentosa in USA (unspecified route) (SanBio pipeline, July 2018)
  • 01 Apr 2018 Preclinical development in Stroke is ongoing in Japan (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top